Are you initiating/discussing peanut OIT in most children less than age 2 due to the benefits of desensitization and remission?

The relative risks and benefits must be weighed as an alternative to omalizumab or in combination with omalizumab. Between 25-40% of patients who are allergic to peanuts are also allergic to at least one tree nut. Although omalizumab has the advantage of providing protection for multiple food allerg...

OIT in this age group may also change the natural history of peanut allergy. At this point, we don’t have data to suggest omalizumab will. As pointed out, omalizumab may facilitate safer OIT, although that is still off-label. There are many factors to consider and discuss when discussing food allerg...